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The paraoxonase (PON) gene family includes three members, PON1, PON2 and PON3, aligned in tandem on
chromosome 7 in humans and on chromosome 6 in mice. All PON proteins share considerable structural homology
and have the capacity to protect cells from oxidative stress; therefore, they have been implicated in the
pathogenesis of several inflammatory diseases, particularly atherosclerosis. The major goal of this review is to
highlight the modulation of each of the PONs by infective (bacterial, viral and parasitic) agents, which may shed a
light on the interaction between infectious diseases and PONs activities in order to effectively reduce the risk of
developing atherosclerosis.
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The desire to understand the correlation between infec-
tion, inflammation and oxidative stress in various dis-
eases, including atherosclerosis, has captured the
imagination of many investigators. The involved
mechanisms are strictly regulated and possibly inter-
connected in order to maintain oxidative homeostasis in
cells and tissues. Understanding the biology and function
of such mechanisms will pave the way for discovery of
novel therapeutic agents in the fight against various in-
flammatory diseases.
The paraoxonases (PONs) comprise a family of closely
related enzymes that includes PON1, PON2 and PON3,
and these are aligned next to one another on chromo-
some 7 in humans and on chromosome 6 in mice. PONs
share around 70% nucleic acid identities and are believed
to be derived from a common precursor [1,2].
In this review, we focused on the effects of infectious
agents on PONs, emphasizing its potential roles against
infections and elucidating the relationship between in-
fection and atherosclerosis.* Correspondence: horii@cc.miyazaki-.ac.jp
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PONs have different cell and tissue distributions, as well
as different regulatory mechanisms, thus suggesting dis-
tinct physiological roles for each of them. These roles,
however, remain largely unknown [3] especially in the
light of the crucial fact that the physiological substrates
of PONs remain still poorly known. Indeed, the most
striking characteristic of PONs is their multitasking cap-
acity, which allows PONs to play a role in several differ-
ent pathways, not only limited to lipid oxidation
metabolism but also including the intriguing field of in-
nate immunity.PON1
PON1 is the most studied member of the PON family
and much of our understanding of the PON enzymes is
derived primarily from studies involving PON1 protein.
In humans, the PON1 gene is mainly expressed in the
liver, giving a protein product of 354 amino acids with a
molecular mass of 43–45 kDa, and is released into nor-
mal circulation [4]. There is growing evidence from ex-
perimental, clinical and epidemiological studies that
underscores the role of PON1 in protection against ath-
erosclerosis [5]; however, the precise mechanisms re-
main elusive.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is screened by using synthetic substrates without regard
for the native substrate or its role in human (patho)biol-
ogy [6]. The ability of PON1 to hydrolyze paraoxon was
employed as a method to measure PON1 activity in sev-
eral species and tissues. PON1 paraoxonase enzymatic
activity can be modulated by polymorphisms in the
PON1 gene locus, including the Q192R polymorphism,
in which glutamine (Q) is replaced by arginine (R) at
position 192. The Q isoform has low activity in hydro-
lyzing paraoxon, while the R isoform shows high activity
[4]. PON1 also possesses arylesterase activity, with
phenyl acetate being one of its best substrates. Further-
more, PON1 exhibits good lactonase activity; hydrolyz-
ing a wide range of lactones [7].
Although PON1’s natural substrates are uncertain,
thioester homocysteine (Hcy)-thiolactone, which is a
product of an error editing reaction in protein biosyn-
thesis formed when Hcy is mistakenly selected by
methionyl-tRNA synthetase, is hydrolyzed to Hcy by
PON1 [3,4]. Therefore, it has been suggested that PON1
should be properly named homocysteine-thiolactonase
[8]. Hcy is a risk factor for the development of cardio-
vascular disease [9]. Proposed mechanisms underlying
Hcy pathobiology include protein modification by Hcy-
thiolactone, oxidative stress, inflammation, autoimmune
response, endothelial dysfunction, and thrombosis [10].
Thus, the Hcy-thiolactonase activity of PON1 is likely to
contribute to the cardioprotective role of PON1.
Most serum PON1 is associated with the cholesterol-
carrying high-density lipoprotein (HDL) (“good choles-
terol”) through its retained N-terminal hydrophobic re-
gion. HDL is important for PON1 secretion and
stabilization by HDL-associated apolipoprotein A-I;
however, less than 5% of serum PON1 is also associated
with chylomicrons and VLDL, but not LDL [11]. Several
lines of evidence have suggested that PON1 protects
against atherosclerosis by its evident ability to guard
low-density lipoproteins (LDL) against oxidative stress,
reduce macrophage foam cell formation, and prevent
atherosclerosis development (Figure 1). In the artery
wall, PON1 inhibits LDL oxidation, in doing so prevents
the ox-LDL-induced up-regulation of monocyte chemo-
attractant protein-1 (MCP-1) production by endothelial
cells [12,13]. MCP-1 displays chemotactic activity for
monocytes into the intima that differentiate into macro-
phages. The latter take up ox-LDL in an unregulated
manner to become foam cells [14], which leads to ath-
erosclerotic plaque development [15,16]. Since the con-
trol of cholesterol efflux is of vital relevance for foam
cell formation, PON1 also enhances cholesterol efflux
from macrophages [17] and inhibits macrophage choles-
terol biosynthesis [18]. Such roles suggest that PON1
has crucial effects on the initial steps of atherosclerosis.The special localization of PON1 in the HDL complex
of human serum led to speculation that the enzyme
plays also an important physiological role in lipid metab-
olism and that it protects against the development of
atherosclerosis [19]. This notion was confirmed by the
capacity of PON1 to hydrolyze lipid peroxides, which
prevents foam cell formation [20]. More interestingly, a
recent study by Deakin et al. [21] showed that PON1 is
not a fixed component of HDL can exert its protective
function outside the lipoprotein environment since it
can be transferred from HDLs to the external face of the
plasma membrane of cells in an enzymatically active
form conferring protection against oxidative stress.
Another important clue regarding the physiological
function of PON1 has been provided by studies in mice
lacking this enzyme. Shih et al. [22] found that PON1
“knockout” (KO) mice develop atherosclerosis when fed
an atherogenic diet, and their HDL, in contrast to wild-
type HDL, failed to prevent LDL oxidation in cultured
artery wall cells. This study clearly established the anti-
oxidative and anti-inflammatory potential of PON1
in vivo and also showed its potential role in the preven-
tion of atherosclerosis. Moreover, mice with combined
PON1/apoE KO exhibited more atherosclerosis than
apoE KO mice and their LDL particles were more sus-
ceptible to oxidation [23]. Furthermore, PON1-deficient
mice showed increased oxidative stress in macrophages,
which could be related to the activation of cellular nico-
tinamide adenine dinucleotide phosphate (NADPH) oxi-
dase and to a decrease in cellular reduced glutathione
(GSH) content. On the other hand, purified PON1 dir-
ectly reduced macrophage oxidative stress [18].
Owing to the development of genetically modified
PON1 KO and transgenic (Tg) mice, the potential roles
of PON1 in the context of macrophage functions could
be studied. HDL from human PON1 Tg mice increased
cholesterol efflux from mouse peritoneal macrophages
(MPM) and the J774 A.1 macrophage cell line via the
ATP-binding cassette (ABCA1) transporter, and the
binding activity to the same macrophage cell types also
increased. In addition, the presence of high PON1 levels
in HDL induced the formation of lysophosphatidylcho-
line (LPC) in the macrophages, which is thought to in-
crease HDL binding to macrophages and thus
contributes to a more important cholesterol efflux via an
apoA-I-mediated mechanism. These results indicate that
PON1 status on HDL particles will influence binding to
macrophages and cholesterol efflux, further demonstrat-
ing the beneficial effects of PON1 in the early stages of
atherosclerosis [17,24].
Recently, the absence of PON1 in mice was associated
with a broad array of vascular changes, including
enhanced oxidative stress and thrombogenicity, as well
as significant increases in leukocyte adhesion and mRNA
Figure 1 A proposed mechanism for atherosclerosis development and the roles of PON1 and PON2 against atherosclerosis. Moving
from left to right, low-density lipoprotein (LDL) diffuses from the blood into the innermost layer of the artery. The LDL in the artery wall is
modified by oxygen radicals to oxidized LDL (oxLDL) which in turn induces endothelial cells to express leukocyte adhesion molecules, such as
vascular cell-adhesion molecule-1 (VCAM1), intercellular adhesion molecule-1 (ICAM-1), and P-selectins. Monocytes and T cells bind to adhesion
molecules-expressing endothelial cells and respond to locally produced chemokines by migrating into the arterial tissue. Monocytes differentiate
into macrophages in response to local macrophage colony-stimulating factor (M-CSF) and other stimuli. Scavenger receptors mediate
macrophage uptake of ox-LDL particles, which leads to intracellular cholesterol accumulation and the formation of foam cells. Ox-LDL and other
ligands promote the production of many pro-inflammatory molecules by macrophages. T cells undergo activation after interacting with antigen-
presenting cells (APCs), such as macrophages or dendritic cells. A T helper 1 (TH1)-cell-dominated response ensues, possibly owing to the local
production of interleukin-12 (IL-12), IL-18 and other cytokines. TH1 cells produce inflammatory cytokines including interferon-α (IFN-α) and
tumour-necrosis factor (TNF). These cytokines and others prompt macrophage activation, production of other pro-inflammatory mediators,
activate endothelial cells, increase adhesion-molecule expression and the propensity for thrombus formation, and stimulate proliferation and
migration of smooth-muscle-cell as well as collagen production. Plaque inflammation might be attenuated in response to the anti-inflammatory
cytokines IL-10 and transforming growth factor-α (TGF-α), which are produced by several cell types including regulatory T and TH2cells,
macrophages, and for TGF-α, also vascular cells and platelets. The atherosclerotic lesion has a core of lipids, including cholesterol crystals, living
and apoptotic cells and a fibrous cap with smooth muscle cells and collagen. Several types of cells of the immune response are present
throughout the atheroma including macrophages, T cells, mast cells and DCs. HDL-associated PON1 inhibits the influx of cholesterol by oxidized
LDL into macrophages by reducing Ox-LDL levels, reducing Ox-LDL uptake via the macrophage scavenger receptor, reducing
macrophage-mediated oxidation of LDL, and increasing the hydrolysis of macrophage oxidized lipids. HDL-associated PON1 also inhibits
macrophage cholesterol biosynthesis and enhances HDL-mediated cholesterol efflux. Monocyte/macrophage-associated PON2 also protects LDL
against oxidation and reduces the oxidative stress caused by preformed ox-LDL. TCR; T-cell receptor, TLR; Toll-like receptor, MCH; Major
histocompatibility complex, ROS; Reactive oxygen species.
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inter-cellular adhesion molecule-1 (ICAM1). Aortic
superoxide production was also significantly higher in
PON1 KO animals when compared with wild-type con-
trols [25].
PON1 may confer protection against macrophage
apoptosis under basal conditions via LPC formation and
further by up-regulation of the macrophage scavenger
receptor class B, type I (SR-BI)-mediated HDL binding
to the cells. As macrophage apoptosis is an important
feature of atherosclerotic plaque development, PON1
deficiency may lead to the enhanced atherosclerosisdevelopment observed in mice, as a result of reduced
SR-BI-mediated HDL protection against apoptosis [26].
More recently, HDL-associated PON1 inhibits
monocyte-to-macrophage differentiation. Monocyte-
derived macrophages play a central role in the develop-
ment of arterial foam cells and atherosclerotic lesions.
Such action could lead to attenuation of macrophage
foam cell formation and atherosclerosis development
[27]. Therefore, PON1 is closely linked to the control of
oxidative stress and inflammation, mainly at the circula-
tion level, where its association with HDL particles is
related to the prevention of atherosclerosis [25,28].
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Human PON2 is ubiquitously expressed and is found in
various tissues with primary localization in the plasma
membrane, which suggests that its functions are distinct
from those reported for PON1 and PON3 [29]. While
little is known about the physiological or pathophysio-
logical role of this protein, PON2 has been reported to
possess anti-oxidant properties. In addition to its ability
to reduce the oxidative stress caused by preformed
mildly oxidized LDL, decreasing LDL-mediated induc-
tion of inflammatory response in cells [29], PON2 can
also protect LDL against oxidation [30]. Thus, one func-
tion of PON2 may be to act as a cellular anti-oxidant,
protecting cells from oxidative stress.
Animal studies have shown that mice subjected to
adenovirus-mediated expression of PON2 (AdPON2) have
an increased anti-oxidant capacity with lower levels of lipid
hydroperoxides when compared to mice treated with either
PBS or empty vector. Although PON2 is not normally
found in circulation and was not detected in the serum of
these mice, its effect may be induced by modulating the
properties of circulating lipoproteins, for example, affecting
the susceptibility of LDL to oxidation and the capacity of
HDL to protect LDL against oxidation [31].
On the other hand, when subjected to a high-fat diet
for 15 weeks, PON2-deficient animals developed signifi-
cantly larger (2.7-fold) atherosclerotic lesions when com-
pared with controls. Moreover, LDL isolated from these
animals was more susceptible to oxidation and induced
a greater degree of monocyte chemotaxis. Furthermore,
there was enhanced macrophage trafficking into the ar-
tery wall in PON2-deficient mice, as determined by
macrophage staining in aortic sections using CD68 as a
marker. When macrophages were isolated from PON2-
deficient mice, they exhibited both higher levels of oxi-
dative stress and enhanced pro-inflammatory properties,
as well as showing increased tumor necrosis factor
(TNF)-α and interleukin (IL)-1β gene expression after
LPS-induced inflammation [32].
PON2 may exert significant protection against macro-
phage triglyceride (TG) accumulation, macrophage TG
biosynthesis, microsomal diacylglycerol acyltransferase 1
(DGAT1) activity and macrophage oxidative stress, in
the presence and absence of glucose [33,34] (Figure 1).
PON2 gene and protein expression have been detected
in various parts of the human gastrointestinal tract [35],
and the addition of purified PON2 to permeabilized in-
testinal Caco-2 cells protects against iron-ascorbate-
induced oxidative stress [36]. Surprisingly, PON2 protein
was detected on the apical (luminal) side of Caco-2 cul-
ture medium, raising the possibility that the intestinal
cells are capable of secreting PON2 into the intestinal
lumen, where it may perform another, as yet unclear
function [35], possibly against infectious agents.PON3
PON3 was the last of the paraoxonases to be character-
ized. Draganov et al. [37] were the first to purify and
characterize rabbit plasma PON3. Several studies then
demonstrated that PON3 protects against oxidation and
inflammation, thus suggesting that PON3 is atheropro-
tective [5,38,39]. Draganov and his colleagues reported
that rabbit PON3 purified from serum was capable of
inhibiting copper-induced LDL oxidation in vitro to a
greater degree than rabbit PON1 [37]. Reddy et al. [40]
showed that pretreatment with cultured human aortic
endothelial cells with supernatants from HeLa Tet On
cell lines overexpressing PON3 prevents the formation
of mildly oxidized LDL and inactivates preformed mildly
oxidized LDL. Rosenblat et al. [30] demonstrated the
presence of PON3 in murine macrophages, but not
human macrophages, which suggests that mouse PON3
influences atherogenesis more directly through its ex-
pression in artery wall cells.
AdPON3 in 26-week-old apolipoprotein E-deficient
mice was also shown to protect against atherosclerosis,
with mice showing significantly lower levels of serum
lipid hydroperoxides and enhanced potential for choles-
terol efflux from cholesterol-loaded macrophages. In
addition, LDL was less susceptible to oxidation, whereas
HDL was more capable of protecting against LDL oxida-
tion. These results confirmed that although human
PON3 in mice did not reside in HDL particles, the re-
duction in atheroma is mediated by the ability of PON3
to enhance the anti-atherogenic properties of plasma
[41].
A study by Shih et al. [42] demonstrated that overex-
pression of human PON3 decreases atherosclerotic le-
sion formation in transgenic mice (C57Bl6/J and
LDLRKO background; 55% and 34% reduction, respect-
ively), in a male-specific fashion. In addition, male
PON3 Tg mice maintained on either low-fat chow or
high-fat Western diet exhibited decreased adiposity
when compared with age and diet-matched, male non-
Tg littermates. Moreover, this study showed that ele-
vated human PON3 expression decreased obesity in
male mice. These findings suggest a protective role for
PON3 against atherosclerosis and obesity.
One of the interesting physiological functions of all
three PONs is the ability, via lactonase activity, to
hydrolyze and inactivate bacterial quorum sensing (QS).
QS molecules are extracellular signals secreted by
Gram-negative bacteria to regulate biofilm formation
and secretion of virulence factors [43,44]. Of the three
PONs, PON2 appears to have the highest activity against
the QS factors. The second member to have evolved is
proposed to be PON3, followed by PON1 [7]. This func-
tion of PONs indicates their potential importance as
novel components of innate immunity.
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tective roles played by PONs against inflammation and
oxidative stress. It is possible that PON2 fulfills these
crucial functions in various organs, whereas HDL-
associated PON1 and PON3 primarily act in blood
circulation.
Mutual relationship between PONs and infections
Numerous risk factors are involved in the development
of atherosclerosis, such as hypertension, cigarette smok-
ing, diabetes, hyperlipidemia and hypercoagulability [45].
However, as many as 50% of patients with atheroscler-
osis lack the abovementioned risk factors, which sug-
gests that there are additional factors predisposing
individuals to atherosclerosis [46,47].
There are multiple epidemiological studies to support
the notion that infections can be considered risk factors
for atherosclerosis. The paradigm that infection by bac-
teria and/or viruses is a risk factor for atherosclerosis via
direct infection of vascular cells or via the indirect
effects of cytokines or acute-phase proteins induced by
infection at non-vascular sites [48] emphasizes the “in-
fectious hypothesis” of atherosclerosis. This relates to
current atherogenesis theories that accept the crucial
role of inflammation in the development of atheroscler-
otic plaques [49]; however, the role of some kind of
infections (like parasitic infection) on atherosclerosis
and related anti-atherogenic mechanisms (including
PONs) remains uncertain.
PONs and bacterial infections
Experimental studies have indicated that PON1 activity
is altered during the acute-phase response. LPS injec-
tion, which mimics Gram-negative infections, in mice
increases serum amyloid A (SAA) through nuclear
factor-κB (NF-κB) transactivation and decreases apoA-I
and PON1 by inhibiting peroxisome proliferator-
activated receptor (PPAR)-α activation. TNF-α, IL-1β
and IL-6 mediate these changes through stimulation of
hepatocytes [50]. Bin Ali et al. [51] also found that LPS
induces a further 50% decrease in hepatic PON1 mRNA
in male mice and moderate increases in female mice
through pro-inflammatory cytokine (IL-1β and TNF-α)-
unmediated pathways. However, these pro-inflammatory
cytokines have been shown to up-regulate (IL-6) or
down-regulate (IL-1β and TNF-α) PON1 gene expres-
sion in HepG2 human hepatoma cells [52].
Similarly to previous results, mice with 18 G cecal
ligation and puncture (CLP) to induce slow leakage of
intestinal flora in the abdominal cavity exhibit gradual
onset sepsis that closely mimics human sepsis. Plasma
paraoxonase activity decreases up to 24 hours post-CLP
in association with increased IL-6 and decreased HDL
levels, and PON1 activity is positively correlated withtotal anti-oxidant activity. The cause-effect relationship
between decreased PON1 activity and increased oxida-
tive stress has not been established, but it is most likely
a dynamic bi-directional relationship [53].
Human clinical studies have shown that in septic
patients there are significant decreases in plasma PON1
(paraoxonase and arylesterase) activity, and this is nega-
tively correlated with C-reactive protein (CRP), which is
produced in response to the oxidizing environment
induced by sepsis. This increased binding of free radicals
to PON1 accounts for the decrease in PON1 activity in
the circulation [54].
More recently, Naderi et al. [55] showed that patients
with pulmonary tuberculosis have significantly lower
paraoxonase and arylesterase activities when compared
with healthy subjects. This reduction is most likely due
to imbalance of oxidant/anti-oxidant systems in pulmon-
ary tuberculosis patients, as supported by the findings of
Nezami et al. [56], who found decreased levels of total
anti-oxidant capacity, red blood cell superoxide dismu-
tase activity and whole blood glutathione peroxidase ac-
tivity with increased levels of malondialdehyde in
pulmonary tuberculosis cases, thus suggesting a higher
susceptibility of LDL to oxidation and higher levels of
lipid peroxidation. This environment clearly provides a
higher risk for atherosclerosis.
At the same time, epidemiological studies in humans
indicated that infection by Helicobacter pylori, a poten-
tial cause of atherosclerosis, significantly decreases
serum paraoxonase and arylesterase activities. This de-
crease may be attributed to decreases in HDL-C and, in
part, to increased oxidative stress and inflammatory con-
ditions induced by H. pylori infection [57].
Chlamydia pneumoniae is an obligate intracellular
bacterium that causes acute and chronic respiratory dis-
ease in humans and is associated with an increased risk
of cardiovascular disease [58,59]. Infection of mice with
C. pneumoniae reduces serum PON1 activity and the
anti-inflammatory properties of HDL by repressing gene
expression via serum amyloid A elevation [50]. In
addition, acute infection is associated with an increase in
the frequency of intra-plaque hemorrhage [60]. These
results indicate that C. pneumoniae contributes to the
progression and destabilization of atherosclerotic lesions.
Interestingly, the expression of human PON1 in trans-
genic Drosophila results in increased resistance to infec-
tion by Pseudomonas aeruginosa via inactivation of the
QS factor N-(3-oxododecanoyl)-L-homoserine lactone
(3OC12-HSL) of Pseudomonas [61]. In vitro studies
using PON1 KO mouse serum have shown that PON1 is
important for degradation of 3OC12-HSL [61] through
its lactonase activity [7,62]; thus, playing an important
role in the fight against bacterial biofilm formation [63].
Importantly, chronic P. aeruginosa infection in the lung
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artery under a cholesterol-supplemented diet [64]. As
PON1 has the ability to inactivate QS in Gram-negative
bacteria, it is possible that under physiological condi-
tions, PON1 (mostly with PON2 and PON3) can prevent
the bacterial colonization associated with several pro-
inflammatory factors, including QS molecules and
atherogenic lipids [65]. These results indicate that
PON1, in addition to its anti-atherogenic role, can also
be considered part of the innate immune system [66].
While little is known about its role, PON2 appears to
have the highest activity against QS factors. As the pul-
monary system is a primary site of infection for P. aeru-
ginosa, experiments using airway epithelial cells cultured
from PON2-KO mice and a QS reporter strain of P. aer-
uginosa confirmed a two-fold increase in QS. This indi-
cates that deficiency of PON2 impairs 3OC12-HSL
degradation by airway epithelial cells and that diffusion
of 3OC12-HSL into airway cells is the rate-limiting step
for degradation of the molecule, irrespective of bacterial
density [67]. Thus, PON2 expression does not appear to
affect the growth of P. aeruginosa, but degrades the bac-
terial QS signal.
Knockdown of PON2 by transfecting cells with small-
interfering RNA (siRNA) in human aortic endothelial
cells treated with 3OC12-HSL or oxidized 1-palmitoyl-2
-arachidonoyl-sn-glycero-3-phosphocholine (Ox-PAPC)
resulted in increased pro-inflammatory response (IL-8,
COX2, IL-1β and ICAM-1), apoptosis markers and
unfolded protein response (UPR) [68]. This indicates
that anti-atherogenic effects of PON2 include destruc-
tion of QS molecules.
The P. aeruginosa QS signal 3OC12, which is inacti-
vated by PON2 [67], has the ability to down-regulate
PON2 mRNA, protein and hydrolytic activity in A549
and EA.hy 926 cell cultures. These decreases were at
least partly mediated by increases in cytosolic Ca2+,
which mediates the degradation of PON2 protein and
mRNA [69]. The hydrolytic activity of PON2 was
decreased much more extensively and rapidly than the
protein, indicating a likely post-translational event that
blocks the hydrolytic activity of PON2. These findings
not only support a role for PON2 in the defense against
P. aeruginosa virulence, but also reveal a potential mech-
anism by which the bacterium may subvert the protec-
tion afforded by PON2 [70].
The third member of the PON family, PON3, is
expressed in the skin, salivary gland, glandular epithe-
lium of the stomach, intestine, liver hepatocytes, pancre-
atic acinar cells, heart, adipose tissue and bronchiolar
epithelium, with differences in distribution patterns be-
tween humans and mice [35,39,71]. To date, there has
been relatively little learned about PON3. However, in
addition to its anti-atherogenic and anti-obesity effects[41,42], PON3 is known to hydrolyze bacterial QS mole-
cules, such as 3OC12-HSL [7,63]; therefore, it is plaus-
ible that the presence of PON3 plays a protective role
against bacterial infection.
PONs and viral infections
Several epidemiological studies have assessed the associ-
ation between viral infection and the development of
atherosclerosis (Table 1). In the late 1970s, experimental
infection of germ-free chickens with an avian herpes-
virus induced an arterial disease that resembled human
atherosclerosis [72].
Experimental study has shown that intranasal inocula-
tion of influenza A strain WSN/33 in C57BL/6 J mice
results in significant decreases in the activities of paraox-
onase and the platelet-activating factor acetylhydrolase,
which reached their lowest levels by day 7 after infec-
tion. This was associated with lower HDL anti-
inflammatory properties and increased monocyte/
macrophage trafficking into arteries. If this is the case in
human infection, these changes might explain the
increased risk for heart attack and stroke after influenza
infection [76].
Hepatitis C virus (HCV) is a major cause of viral hepa-
titis. There are approximately 170 million people world-
wide who are chronically infected by this virus. Infection
by HCV does not typically resolve, and nearly 80% of
infected individuals become chronic carriers who may
then progress to severe liver diseases [97]. HCV infec-
tion is associated with increased oxidative stress, which
is marked by an increase in oxidants and a decrease in
anti-oxidant capacity of the cells [97]. In addition to the
contribution by chronic inflammation caused by infec-
tion, direct induction of reactive oxygen species/reactive
nitrogen species (ROS/RNS) and mitochondrial dysfunc-
tion by the virus is likely.
In cell culture systems, HCV expression, replication
and infection can induce oxidative stress [98-100]. Sub-
sequently, oxidative stress has been identified as a sig-
nificant mechanistic pathway culminating in the
development of hepatic damage [101]. As PON1 exerts a
protective effect against oxidative stress, it is plausible
that there is an association between this enzyme and
liver impairment. A study by Ali et al. [77] confirmed
that there were significant decreases in PON1 (paraoxo-
nase and arylesterase) activity in chronic and cirrhotic
HCV patients with higher serum nitric oxide levels and
myeloperoxidase activity. These results are consistent
with those of Ferré et al. [102], who studied rats with
carbon tetrachloride-induced fibrosis and showed
decreased PON1 activity and an inverse correlation with
lipid peroxidation, while the addition of zinc as an anti-
oxidant was associated with enhanced PON1 activity
and normalization of lipid peroxidation. These results
Table 1 Potential infectious causes of atherosclerosis and/or underlying diseases




LPS Human PON1 # Oxidative stress and oxidative
modification of HDL
+ [53,54]




(female) PON1 "# • Increased hepatic PON1 synt esis
(in case of ")
• Oxidative stress (in case of #
+ • [51]
• [53,74]




HepG2 human hepatoma cells PON1 # (IL-1β and TNF-α)-mediated
hepatic PON1 down-regulation
[52]
HepG2 human hepatoma cells PON1 " (IL-6)-mediated hepatic PON1
up-regulation
[52]
Pulmonary tuberculosis Human PON1 # Oxidant/anti-oxidant
systems imbalance
+ [55]
Helicobacter pylori Human PON1 # Oxidative stress and
oxidative modification of HDL
+ [57]
Chlamydia pneumoniae Mice PON1 # Down-regulate hepatic
PON1 mRNA
+ [50]
Pseudomonas aeruginosa A549 and EA.hy 926
cell cultures
PON2 # Down-regulate PON2 mRNA [69]
Viral infections
Influenza A strain WSN/33 C57BL/6 J mice PON1 # Decreased hepatic PON1
protein synthesis
+ [76]
Hepatitis C virus (HCV) Human PON1 # Oxidant/anti-oxidant
systems imbalance
+ [77]
HCV Human PON3 " Oxidant/anti-oxidant
systems imbalance
+ [78]
Hepatitis B virus (HBV) Human PON1 # • Oxidant/anti-oxidant systems mbalance
• Decrease (dysfunction) of HD
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ble 1 Potential infectious causes of atherosclerosis and/or underlying diseases (Continued)
V Human PON3 " Oxidative stress + [86]
Parasitic infections
ypanosoma cruzi (Chagas’ disease) Human PON1
PON2
PON3
± • Oxidative stress,
apoA-I miss structure
• TH1 immune polarization
± • [87]
• [88-91]





ichinella spiralis Rat PON1 # Oxidant/anti-oxidant
systems imbalance
± [95]
histosoma mansoni Mice Hepatic
PON1
# Oxidative stress — [96]
e arrows " and # represent increased and decreased PONs activity.
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against free radical production in liver organelles.
Although PON1 enzyme activity is a more important
factor in atherosclerosis and coronary heart disease than
PON1 genotype [103,104], it is interesting to observe
that there was a higher frequency of the RR isoform of
the 192 polymorphism in healthy subjects than in those
with chronic HCV infection [105]. This is supported by
the results of Aviram et al. [106], who found that the
PON1Q allele appears to be more efficient than the
PON1R allele in hydrolyzing lipid peroxides in both cor-
onary and carotid lesion homogenates. Mackness et al.
[103] also showed that the R allele is associated with a
modest increase in the risk of coronary heart disease.
On the other hand, serum PON3 concentration, in
patients with chronic hepatic impairment as a conse-
quence of HCV infection, is significantly elevated when
compared with control subjects, and its concentration is
related to the severity of the periportal alterations and to
serological markers of anti-apoptosis, thus suggesting an
anti-apoptotic role for PON3 [78].
Another type of hepatitis caused by viral infection, hepa-
titis B, also showed lower serum paraoxonase and aryles-
terase activities in chronic active hepatitis B patients when
compared with inactive carriers and control individuals
[80]. This observation is supported by the results of Schul-
pis et al. [79], who found decreased paraoxonase and ary-
lesterase activities in mothers with HBV disease, mostly
due to the liver damage and low total anti-oxidant cap-
acity. This reduction of serum PON1 activity during HBV
infection may be the result of changes in synthesis or se-
cretion of HDL [107], and significant decreases [81] and
post-transcriptional modification of nascent ApoA-1 [82].
It is likely that PON1 protects HDL from oxidation and
this is likely to be related to the attributed HDL-anti-
apoptotic function [79]; therefore, PON1 may contribute
to the protective effects of HDL in maintaining lower
levels of HBV DNA [108].
Several prospective and retrospective studies have
established the association between human immunodefi-
ciency virus (HIV) infection and atherosclerotic coron-
ary artery disease [109]. Inflammation has been
recognized as the key pathologic process leading to early
atherosclerosis. Patients with HIV have an enhanced
state of inflammation. Several specific pathways of in-
flammation linking HIV infection to increased cardio-
vascular risk have been elucidated. HIV-infected
individuals have higher CRP values and higher circulat-
ing concentrations of the adhesion molecules intercellu-
lar adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1), as compared with un-
infected individuals [110,111].
There are several key changes in lipoprotein metabol-
ism in the course of HIV infection, including increasedlipid peroxidation, hypocholesterolemia and hypertrigly-
ceridemia, and decreased HDL concentration [83]. This
explains the significant decrease in serum PON1 activity
in HIV-infected patients [84]. Anti-retroviral therapy
using non-nucleoside reverse transcriptase inhibitors
such as nevirapine increases HDL concentration and
apoA-I production. Concomitantly, modest increases in
lecithin:cholesterol acyltransferase and cholesteryl ester
transfer protein activity are also observed [112]. It is
likely that apoA-I increases the stability and activity of
PON1 [113] in treated patients, which may contribute to
the beneficial effects of high HDL concentration in HIV-
infected patients.
Changes in PON1 activity play a role in the course of
HIV infection, which is an area that is worthy of further
investigation. PON1 may also play an anti-infective role,
as this enzyme increases cholesterol efflux from the cell,
as well as the binding of the HDL particle to its receptor
(ABCA1) [17]. Membrane metabolism is modulated by
the efflux of cholesterol to the HDL particle, and this
phenomenon would influence HIV replication, as the
virus requires cholesterol rafts in the plasma membrane
for final assembly and entry into the cell. In addition,
there is a positive association between serum PON1 ac-
tivity and CD4+ T lymphocyte count and its serum con-
centration with β-2-microglobulin; the latter being an
effective marker of HIV infection activity [84].
In contrast to PON1 activity during HIV infection,
both in vitro and in vivo studies have shown increased
PON2 activity and up-regulation of cellular PON2
mRNA expression upon HIV-1 infection in the CD34
+CD4+ hematopoietic cell line TF-1 and in thymocytes
derived from the human fetal conjoint thymus/liver
hematopoietic organ of SCID-hu mice. HIV-1 infection
results in dephosphorylation of STAT5 in the absence of
granulocyte-macrophage colony stimulating factor
(GM-CSF), and this is associated with increases in
PON2 gene expression, activity and protein levels, thus
indicating that PON2 is part of the innate immune re-
sponse to viral infections [85].
On the other hand, PON3 concentrations also increase
significantly (about three times) in HIV-infected patients
with respect to controls and are inversely correlated with
oxidized LDL levels, which indicates that PON3 plays a
protective role against oxidative stress and increased
lipid peroxidation in HIV infection [86]. Long-term use
of non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based anti-retroviral therapy is associated with
a decrease of PON3 concentrations. NNRTI promotes
anti-atherogenic changes in HDL form and function, in-
cluding normalization of size and lipid composition and
enhancement of reverse cholesterol transport, and
induces higher PON1 activity [114,115]. These effects,
together with the increased concentration before
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presence of sub-clinical atherosclerosis in HIV-infected
patients, although lipid peroxidation and atherosclerosis
are known to be strongly linked to such infection [116].
Therefore, PON3 is in some way involved in protection
against HIV infection [86].
PONs and parasitic infections
In the battle against parasitic infection, host immune
response is central, but this also carries a cost. For ex-
ample, generation of oxidative stress is an important fac-
tor in immune activation [117]. The generation of
oxidants during parasitic infection occurs via three
routes: first, they are released by immune cells that use
their cytotoxic effects to kill the pathogen; second, oxi-
dants are by-products of oxygen consumption, and
increased metabolic activity during an immune response
may contribute to the generation of additional toxic oxi-
dants; and third, parasites themselves can be directly re-
sponsible for oxidant release through degradation
products of their own metabolism. While useful in im-
mune protection, non-targeting toxic oxidants have a
potentially important negative side-effect by damaging
host tissues and obstructing their function [118].
Considering the “oxidative modification hypothesis” of
atherogenesis [16,119], together with the chronicity of
several types of parasitic infection that can influence the
host for years to decades [120,121], discussing the effects
of parasitic infections and their associated immune
responses on PON activity in the context of atheroscler-
osis remains of clinical importance.
The protozoan parasite Trypanosoma cruzi causes
Chagas’ disease, which is a major endemic problem from
the southern United States to temperate South America
[122]. Infection invokes alteration in the microvascular
and macrovascular circulation and severe cardiomyop-
athy [123]. Although epidemiological studies in humans
did not show a direct linkage between Chagas’ disease
and atherosclerosis [124], experimental studies, using
in vivo and in vitro models, demonstrated cellular infil-
tration (CD8+ and CD4+) and associated cytokine (IL-4,
IL-5, IL-6 and TNF-α) production in the heart [88,89].
Further studies showed increased expression of ICAM-1,
IL-6 and TNF-α in aortic endothelial cells with asso-
ciated inflammation in the adventitia consisting mainly
of CD4+ and CD8+ T cells and macrophages [125]. A re-
cent study indicated that immune response polarization
to a TH1 response during experimental T. cruzi infection
is responsible for the development of the chronic cardiac
form of the disease [90,91].
On the other hand, T. cruzi infection was found to in-
duce oxidative stress in the host indicated by increased
levels of TBARS and SOD [87]. Interestingly, HDL
meets some of the nutritional needs of T. cruzi, assupported by the observation that epimastigote growth
is slowed significantly in vitro by lipid depletion and that
transition of T. cruzi trypomastigotes to amastigotes is
accompanied by a shift from carbohydrate to lipid-
dependent energy metabolism [126,127]. Furthermore,
exposure of cruzipain to human HDL during in vitro
and in vivo infection in mice with T. cruzi generates sev-
eral truncated apoA-I fragments [126]. Importantly,
apoA-I, which is the major structural and functional
protein component of HDL and is necessary for stabiliz-
ing and maintaining the optimum PON1 activity
[113,128], was mostly truncated in T. cruzi in the sera of
human patients when compared with controls [126].
Raper et al. [129] demonstrated the presence of apoA-I
and PON1 in both trypanosome lytic factors (TLF1 and
TLF2) in human serum. In humans, these factors confer
resistance to infection with cattle T. brucei brucei. The
authors suggested that the presence of apoA-I, regard-
less of its concentration, is important in the assembly of
lytic particles, as supported by the finding that serum
from an individual with familial apoA-I deficiency is not
trypanolytic [130]. Further studies confirmed that PON1
influences survival in mice infected with T. congolense;
mice overexpressing PON1 had significantly longer life-
spans than wild-type mice, and mice deficient in PON1
had significantly shorter lifespans [131].
The possible mechanisms by which PON1 may influ-
ence trypanosome virulence may be related to the role of
PON1 in the immune response. PON1 has been shown to
have anti-inflammatory properties [13,132]. This is sup-
ported by the observed trypanosome survival of a rela-
tively short period of time (less than 10 days) after
infection, thus indicating that it may be function of innate,
rather than adaptive, immunity [131]. PON1 also has mul-
tiple enzymatic activities, including esterase and lactonase,
which may be important against trypanosome infection.
The effects of the second most common parasitic
infections caused by nematodes on PON1 activity were
studies by Farid et al. [92,93] who showed that infection
by Nippostrongylus brasiliensis, a gastrointestinal nema-
tode that infects mice and rats and has a similar life
cycle as human pathogens Ancylostoma duodenale and
Necator americanus [133], reduces serum PON1 activity
in male rats. Studies by the same group showed that
N. brasiliensis infection in rats fed a high-fat diet led to
reduced serum PON1 activity in association with an
atherogenic lipid profile [94].
At least two possible mechanisms can be postulated
for the observed decrease in PON1 activity during
N. brasiliensis infection. The infected rats had down-
regulated hepatic PON1 expression, which is closely
correlated with serum PON1 activity [4,75,134]. The
mechanism by which hepatic PON1 mRNA is down-
regulated during N. brasiliensis infection in rats is
Farid and Horii Lipids in Health and Disease 2012, 11:92 Page 11 of 15
http://www.lipidworld.com/content/11/1/92induction by various pro-inflammatory cytokines asso-
ciated with that infection. This notion is supported by
the up-regulation of hepatic IL-1β, IL-1β receptor (R),
TNF-α and TNFR1 mRNA expression. These results are
consistent with the observation of increased serum levels
of pro-inflammatory cytokines (IL-1, IL-6 and TNF-α)
on day 9 after infection with N. brasiliensis [92], which
provides evidence that hepatic PON1 mRNA is down-
regulated during N. brasiliensis infection in response to
inflammatory conditions either in hepatic tissue or
induced during larval migration. The role of pro-
inflammatory cytokines in down-regulation of PON1
mRNA is primarily mediated by NF-κB [50,52].
An alternative or complementary explanation is the
increased levels of oxidative stress parameters (TBARS)
[94] as a result of host immune-dependent damage to
helminth parasites via a nonspecific defense reaction by
the host [135]. These results in enhanced free radical
production and oxidatively damaged macromolecules,
and PON1 enzyme can be inactivated by these com-
pounds [136]. This is supported by the results recently
obtained by Mido et al. [95].
Another interesting finding was reported by Chelur
et al. [137], who confirmed expression of PONs in the
nematode Caenorhabditis elegans system. The expressed
PONs are thought to interact with lipids, and this inter-
action may be crucial to the localization of the degenerin
channel complexes to the specialized membrane
domains mediating mechanotransduction in touch cells
of the nematode.
The opposite appears to be the case for the third para-
sitic category of trematodes. The results obtained by
Doenhoff et al. [138] showed that atherogenesis is reduced
by approximately 50% when compared with uninfected
controls in apoE−/− mice subjected to low-intensity,
chronic experimental infection with Schistosoma
mansoni. The authors attributed this to parasite-
mediated effects on lipid metabolism. As schistosomes
do not synthesize cholesterol [139] and the parasite
breaks down LDL [140] via inducible LDL receptors, this
would account for the decrease in blood cholesterol
levels in infected animals. Alternatively, schistosome in-
fection may reduce circulating lipid levels by inhibiting
lecithin:cholesterol acyltransferase (LCAT) activity [141].
The mechanism by which schistosomiasis reduces ath-
erosclerotic lesion development appears to be inde-
pendent of the development of a TH2 environment, as
exposure to eggs induces a classic TH2 response (IL-4,
IL-5 and IL-13 production) but does not alter lesion
progression [142,143].
The involvement of TH2 cells in atherosclerosis is am-
biguous, but the notion is supported by the work of
Stanley et al. [144], who found that the lipid-lowering
effects of parasite eggs may be induced as a consequenceof a granulomatous reaction against tissue-embedded
eggs, rather than a direct response to the eggs them-
selves. These results are supported by a study by Helmy
et al. [96], who showed that serum and liver arylesterase
and paraoxonase activities were significantly lower in
mice at 10 weeks after infection with S. mansoni, as
compared to uninfected healthy mice. However, these
activities are partially restored in infected animals receiv-
ing zinc as an anti-oxidant, indicating that the changes
in PON1 are influenced by oxidative stress associated
with infection.
As there are no more detailed studies on the relation-
ship between parasitic infection and PONs, particularly
PON2 and PON3, further mechanistic investigations
would be valuable in exploring the measures to counter-
act the inflammatory and oxidative processes in parasitic
infections and in providing new insights into the roles
played by these infections during atherogenesis regard-
ing that the typical immune response in the initial steps
of atherogenesis is TH1 [145-147]. Switching the im-
mune response from TH1 to TH2, which occurs in some
parasitic infections, may induce secretion of the anti-
inflammatory cytokines, leading to slower progression of
atherosclerotic lesion development [146,148].
Conclusion
There is now growing evidence that PONs acting alone
or in concert with other mechanistic pathways prevent/
retard atherosclerosis development in vivo. Under
conditions such as infection, the anti-inflammatory and
anti-atherogenic properties of PONs are reduced by pro-
inflammatory proteins and/or associated oxidative stress.
Therefore, detailed biochemical, cell-based, animal and
epidemiological studies are necessary to further identify
the physiological roles of PONs and the molecular
mechanisms by which PONs render their protective
effects against atherosclerosis. Future studies on the po-
tential implications of PONs activity modulation (e.g. by
means of recombinant human PON engineered for spe-
cific molecular target) during infectious disease are of
great importance. In addition, it is of particular interest
to speculate on a broader host defense role for PONs
against bacterial, viral and parasitic infections.
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